William Blair Investment Management LLC Buys New Holdings in Merit Medical Systems, Inc. $MMSI

Key Points

• William Blair Investment Management initiated a position of 1.14 million Merit Medical Systems shares worth approximately $78.9 million, representing 1.91% of the company. Institutional investors collectively own 99.66% of MMSI.
• Analysts maintain a positive outlook, with eight Buy ratings and four Holds producing a consensus “Moderate Buy” rating and an average price target of $100.
• Merit Medical exceeded quarterly expectations, reporting $1.19 in EPS versus $0.96 expected and revenue of $418.84 million, up 9.5% year over year. The company issued fiscal 2026 EPS guidance of $4.25 to $4.35.

William Blair Investment Management LLC purchased a new position in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,137,790 shares of the medical instruments supplier's stock, valued at approximately $78,894,000. William Blair Investment Management LLC owned 1.91% of Merit Medical Systems at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Los Angeles Capital Management LLC purchased a new stake in shares of Merit Medical Systems during the fourth quarter valued at approximately $25,000. Kilter Group LLC bought a new position in shares of Merit Medical Systems in the second quarter worth approximately $25,000. Torren Management LLC purchased a new position in shares of Merit Medical Systems in the fourth quarter worth $38,000. Covestor Ltd increased its stake in shares of Merit Medical Systems by 252.6% in the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier's stock worth $41,000 after buying an additional 336 shares during the period. Finally, Danske Bank A S bought a new stake in Merit Medical Systems during the 3rd quarter valued at $42,000. Institutional investors own 99.66% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Piper Sandler increased their price target on shares of Merit Medical Systems from $96.00 to $106.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Needham & Company LLC boosted their price objective on shares of Merit Medical Systems from $90.00 to $101.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Robert W. Baird set a $98.00 price objective on shares of Merit Medical Systems in a research note on Friday, July 31st. Barrington Research set a $114.00 target price on shares of Merit Medical Systems in a report on Friday, July 31st. Finally, Canaccord Genuity Group raised their target price on Merit Medical Systems from $85.00 to $94.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $100.00.

Merit Medical Systems Price Performance

MMSI stock opened at $90.78 on Friday. Merit Medical Systems, Inc. has a 1 year low of $59.74 and a 1 year high of $94.75. The company has a market cap of $5.42 billion, a P/E ratio of 37.51, a PEG ratio of 2.27 and a beta of 0.49. The firm has a 50-day moving average of $77.41 and a 200 day moving average of $72.57. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.20 and a quick ratio of 2.79.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, topping the consensus estimate of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The business had revenue of $418.84 million during the quarter, compared to analyst estimates of $405.25 million. During the same period last year, the business posted $1.01 earnings per share. Merit Medical Systems's quarterly revenue was up 9.5% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, sell-side analysts forecast that Merit Medical Systems, Inc. will post 3.81 EPS for the current year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source